Patents by Inventor Klaus-Peter Kuenkele

Klaus-Peter Kuenkele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10858438
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • Patent number: 10793621
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: October 6, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Publication number: 20200199222
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 25, 2020
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Patent number: 10611825
    Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: April 7, 2020
    Assignee: HOFFMANN LA-ROCHE INC.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Patent number: 10597449
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 24, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • Publication number: 20180344868
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Publication number: 20180312573
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg-Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN
  • Publication number: 20180179287
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG
  • Patent number: 9982036
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 29, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Publication number: 20180037633
    Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 12, 2017
    Publication date: February 8, 2018
    Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN
  • Patent number: 9724425
    Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: August 8, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
  • Publication number: 20170174762
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 22, 2017
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Publication number: 20150099699
    Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 9, 2015
    Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
  • Publication number: 20140193404
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Application
    Filed: March 3, 2014
    Publication date: July 10, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Patent number: 8703919
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: April 22, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Publication number: 20120322732
    Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
    Type: Application
    Filed: July 18, 2012
    Publication date: December 20, 2012
    Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
  • Publication number: 20120237507
    Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 27, 2012
    Publication date: September 20, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Publication number: 20120237506
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Application
    Filed: February 27, 2012
    Publication date: September 20, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
  • Publication number: 20120149879
    Abstract: The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 14, 2012
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Christian Gerdes, Eike Hoffmann, Christian Klein, Klaus-Peter Kuenkele, Wolfgang Schaefer, Jan Olaf Stracke, Pablo Umana
  • Publication number: 20120128664
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 24, 2012
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher